Market Overview

Why Novus Therapeutics Is Trading Lower Today


Novus Therapeutics (NASDAQ: NVUS) shares are trading lower on Tuesday.

Ladenburg Thalmann downgraded the stock from Buy to Neutral and announced a price target of 60 cents per share.

Novus Therapeutics Inc is engaged in the biotechnology sector. As a pharmaceutical company, it is focused on the acquisition, development, and commercialization of ear, nose, and throat related products.

Novus shares were trading 11.79% lower at 54 cents at the time of publication on Tuesday. The stock has a 52-week high of $1.82 and a 52-week low of 25 cents.

Related Links:

UK Clears Gilead's Remdesivir For Some Coronavirus Patients

Gilead Analysts See Questionable Commercial Opportunity For Coronavirus Candidate Remdesivir

Latest Ratings for NVUS

Jun 2020Ladenburg ThalmannDowngradesBuyNeutral
Nov 2019H.C. WainwrightInitiates Coverage OnBuy
Sep 2018Ladenburg ThalmannInitiates Coverage OnBuy

View More Analyst Ratings for NVUS
View the Latest Analyst Ratings


Related Articles (NVUS)

View Comments and Join the Discussion!

Posted-In: why it's movingPenny Stocks Downgrades Price Target Analyst Ratings

Latest Ratings

WIXRaymond JamesMaintains340.0
PZZAStephens & Co.Maintains108.0
CHUYStephens & Co.Maintains21.0
UPLDRaymond JamesMaintains45.0
XLRNSVB LeerinkMaintains134.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at